|1.||Smith, Jonathan: 5 articles (01/2015 - 03/2013)|
|2.||Birgegård, Gunnar: 5 articles (04/2014 - 05/2004)|
|3.||Steurer, Michael: 4 articles (06/2015 - 11/2004)|
|4.||Molinas, F C: 4 articles (04/2015 - 01/2000)|
|5.||Marta, R F: 4 articles (04/2015 - 01/2000)|
|6.||Gisslinger, Heinz: 4 articles (03/2013 - 11/2004)|
|7.||Samuelsson, Jan: 4 articles (01/2013 - 05/2004)|
|8.||Cacciola, Emma: 4 articles (12/2011 - 09/2004)|
|9.||Gugliotta, Luigi: 3 articles (06/2015 - 12/2011)|
|10.||Wilde, Paul: 3 articles (01/2015 - 02/2014)|
03/01/2013 - "Although anagrelide is widely used for the treatment of essential thrombocythemia (ET) in the USA and Europe, it is not licensed in Japan. "
05/01/2008 - "We can conclude that anagrelide is an effective and safe drug for pretreated patients with essential thrombocythemia."
01/01/2000 - "We present herein studies carried out in 17 patients with essential thrombocythemia before treatment with anagrelide and on remission. "
07/01/2000 - "Essential thrombocythemia-related microvascular thrombotic and hemorrhagic symptoms disappeared with the normalization of platelet count in all cases during maintained remission of essential thrombocythemia by long term continuous anagrelide treatment with a follow-up period of between 2 and 6 years. "
07/01/2000 - "The platelet counts before anagrelide treatment and during maintained remission of essential thrombocythemia by anagrelide were 980 (range, 610-2030) and 378 (range, 212-546) x 10(9)/L, respectively. "
10/01/2003 - "These patients received anagrelide for 25 months resulting in a significant improvement of thrombocytosis. "
07/26/1998 - "A new drug, anagrelide is effective in the treatment of myeloproliferative thrombocytosis and thrombocythemia."
01/01/1992 - "Our experience suggests that anagrelide should become a useful agent in controlling the thrombocythemia seen in chronic myeloproliferative diseases and can be effective in patients in whom treatment with currently available agents has failed."
01/01/1992 - "To evaluate the safety and efficacy of anagrelide when used to reduce platelet counts in patients with thrombocytosis. "
11/01/2004 - "Herein, we report the results of a long-term study of patients with ET treated with anagrelide to control thrombocytosis. "
|3.||Myeloproliferative Disorders (Myeloproliferative Disorder)
01/01/2007 - "A multicenter, open, phase II study of anagrelide treatment in 60 patients during 2 yr was performed by the Swedish Myeloproliferative Disorder Study Group. "
05/01/2004 - "A multicenter, open, phase II study of anagrelide treatment was performed by the Swedish Myeloproliferative Disorder Study Group. "
05/01/2008 - "This makes anagrelide adequate for the treatment of chronic myeloproliferative disorders characterized by marked thrombocytemia. "
06/01/2006 - "Anagrelide (ANA) and hydroxycarbamide (HC) are two distinct pharmacological agents used to treat thrombocythaemia associated with myeloproliferative disorders. "
05/01/2006 - "Aim of patient register is to monitor medical effect of anagrelide therapy and incidence of adverse effects in patients with ET and other myeloproliferative disorders and subsequent analysis of collected data. "
01/01/2009 - "With regard to long-term safety of anagrelide, the EMEA has required close monitoring of the safety points identified in future Periodic Safety Update Reports and in a Post Authorisation Safety Study in the EU, which will focus especially on cardiovascular events and acute leukemia. "
04/01/2006 - "Anagrelide has recently been registered in Europe as a second-line therapy in ET but is often used as first-line therapy in the United States, especially in younger patients, due to the concern about increased leukemia risk with cytostatic treatment. "
05/01/2005 - "With maximum follow-up over 7 years, anagrelide achieved platelet control in over 75% of MPD patients and did not increase the conversion to acute leukemia during the treatment duration analyzed. "
06/01/2002 - "Given that many commonly used medical interventions cost in the range of $50,000 to $100,000 per year of life gained, and the generally poor outcome associated with treatment-related leukemia that can result from hydroxyurea, anagrelide could be considered a therapeutic alternative that is clinically effective at an acceptable cost."
06/01/2002 - "The results were very sensitive to the risk of leukemia caused by hydroxyurea, with an incremental cost-effectiveness of anagrelide compared with hydroxyurea of $156,969 per additional year of life gained if the lifetime leukemia risk drops from a baseline of .08 to.05. "
06/01/2013 - "In conclusion, the treatment strategy according to the CZEMP guidelines incorporating anagrelide is highly effective in reducing the platelet counts, strongly prevents venous events, reduces arterial events, and leads to an increase of minor hemorrhages."
01/01/2006 - "The design of the PT1 study has been queried with respect to the heterogeneous nature of the study population (possible inclusion of patients with early myelofibrotic disease) and the concomitant use of aspirin (interaction with anagrelide causing increased bleeding events). "
06/01/2006 - "The combination of anagrelide with acetylsalicylic acid may be contraindicated in patients with a history of bleeding."
11/01/2015 - "The aim of this study was to meta-analyze currently available data comparing anagrelide to hydroxyurea for reduction of rates of thrombosis, bleeding and death among patients with ET. "
01/01/2006 - "This trial also indicated that the incidence of the secondary endpoints transient ischaemic attack and gastrointestinal bleeding favoured hydroxycarbamide plus aspirin, while the incidence of venous thrombosis favoured anagrelide plus aspirin. "
|2.||Aspirin (Acetylsalicylic Acid)
|3.||Interferon-alpha (Interferon Alfa)
|4.||Reticulin (Reticular Fiber)
|8.||pro-brain natriuretic peptide (1-76)
|1.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
|3.||Stem Cell Transplantation
|4.||Renal Dialysis (Hemodialysis)
|5.||Drug Therapy (Chemotherapy)